Aditya Bulusu, MD
Urology · Saginaw, MINPI 1982697074
Payments from drug & device makers
Across 176 payments — averaging $34.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teleflex LLC$2K
- Procept Biorobotics Corporation$782
- Medtronic$709
- Calyxo, Inc.$366
- AstraZeneca$338
- Johnson & Johnson$327
- plus $2K from 30 others
What the payments were for
- Consulting fees$3506%
- Travel & lodging$1,71328%
- Food & beverage$3,79663%
- Education$1883%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teleflex LLC | 24 | $1,664 |
| Procept Biorobotics Corporation | 1 | $782 |
| Medtronic(2 entities) | 41 | $709 |
| Calyxo, Inc. | 2 | $366 |
| AstraZeneca | 9 | $338 |
| Johnson & Johnson | 14 | $327 |
| Sumitomo Pharma America, Inc. | 12 | $180 |
| Astellas Pharma US Inc | 8 | $175 |
| Merck | 6 | $164 |
| Ferring Pharmaceuticals Inc. | 5 | $119 |
| Myriad Genetic Laboratories, Inc. | 5 | $116 |
| Novartis | 4 | $109 |
| Olympus America Inc. | 6 | $104 |
| Coloplast | 5 | $83 |
| Pfizer | 4 | $79 |
| Bayer | 4 | $79 |
| Urovant Sciences Inc | 1 | $67 |
| Urogen Pharma, Inc. | 2 | $62 |
| Verity Pharmaceuticals Inc. | 2 | $50 |
| Sight Sciences, Inc. | 1 | $45 |
| Tolmar, Inc. | 2 | $40 |
| Accord Healthcare, Inc. | 2 | $37 |
| Endo USA, Inc. | 2 | $36 |
| Smith+Nephew | 2 | $36 |
| Palette Life Sciences, Inc. | 1 | $35 |
| Janssen Scientific Affairs, LLC | 1 | $31 |
| Avyxa Pharma, LLC | 1 | $28 |
| Organon | 1 | $27 |
| Dendreon Pharmaceuticals LLC | 1 | $24 |
| AbbVie | 1 | $23 |
| Photocure Inc | 1 | $22 |
| Valencia Technologies Corporation | 1 | $22 |
| Antares Pharma, Inc. | 1 | $20 |
| Laborie Medical Technologies Corp. | 1 | $17 |
| Bioprotect Medical, Inc. | 1 | $16 |
| Alnylam Pharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UroLift$931
- AquaBeam Robotic System$782
- CVAC$350
- INTERSTIM$174
- LYNPARZA$100
How this compares
$6,048 in reported general payments places this provider in the 65th percentile of 400 urology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 204 | $2,886,395 |
| MyrbetriqMirabegron | 276 | $232,473 |
| Mirabegron ErMirabegron | 78 | $68,083 |
| GemtesaVibegron | 77 | $67,754 |
| Tamsulosin Hcl | 2,002 | $48,387 |
| Abiraterone Acetate | 29 | $42,705 |
| Trospium Chloride | 265 | $28,297 |
| ElmironPentosan Polysulfate Sodium | 14 | $19,336 |
| Oxybutynin Chloride ErOxybutynin Chloride | 448 | $14,834 |
| Potassium Citrate ErPotassium Citrate | 79 | $12,470 |
| Finasteride | 435 | $9,852 |
| Dutasteride | 226 | $9,415 |
| Bethanechol Chloride | 83 | $7,069 |
| Cephalexin | 379 | $5,907 |
| Tolterodine Tartrate ErTolterodine Tartrate | 38 | $5,210 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $175 | $3,118,868480 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $180 | $67,75477 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $31 | $42,70529 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 400 urology providers in Michigan.
Other urology in Saginaw
- Richard MillsSaginaw$217K
- Sanjeev KaulSaginaw$20K
- Jason HafronWest Bloomfield$9.9M
- Ashok ReddySterling Heights$4.9M
- Kenneth KernenTroy$3.4M
- James PeabodyDetroit$2.1M
- William RobertsAnn Arbor$973K
- Adam GadzinskiRoyal Oak$727K
- William JohnstonLivonia$675K
- Kenneth PetersRoyal Oak$590K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.